Phreesia, Inc.
23.22-0.19 (-0.81%)
Oct 29, 4:00:02 PM EDT · NYSE · PHR · USD
Key Stats
Market Cap
1.39BP/E (TTM)
-Basic EPS (TTM)
-0.42Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Phreesia swung to a $0.7M net profit in Q2 FY2026 ended July 31, 2025, from a $18.0M loss a year earlier, as total revenue climbed 15% y/y to $117.3M on 10% subscription growth to $53.7M, 12% payment fees to $28.4M, and 25% network solutions to $35.2M; operating loss narrowed to $1.5M from $17.2M, with gross margin steady at 85.2% (derived). YTD revenue rose 15% to $233.2M, but net loss widened slightly to $3.3M from $3.7M, reconciling to Q1's $3.9M loss; diluted EPS of $0.01 matched basic on 61.7M shares, with no anti-dilution flagged. Cash hit $98.3M, up from $84.2M at FYE, with $29.7M YTD operating cash flow and $17.1M free cash flow (derived as operating cash minus $12.6M capex); total debt fell to $11.7M from $16.2M, supported by a $50M undrawn Capital One revolver at 7.4% with covenant compliance. Post-quarter, Phreesia agreed to acquire AccessOne for $160M cash in Q3/Q4 FY2026, funded by cash and bridge debt, to bolster patient financing. Yet competition from EHR systems remains a key risk.
8-K
Phreesia buys AccessOne for $160M
Phreesia inked a $160 million cash deal on August 29, 2025, to snag AccessOne, a receivables financing whiz serving big U.S. health systems with a $450 million portfolio. This bolt-on sharpens Phreesia's payment toolkit, boosting collections sans patient backlash, while locking in no-poach pacts and HSR clearance hurdles. Deal eyes Q3-Q4 close. Integration risks loom if synergies falter.
8-K
Phreesia annual meeting results
Phreesia stockholders convened their annual meeting on June 25, 2025, electing Gillian Munson and Mark Smith, M.D., as Class III directors for three-year terms ending in 2028, despite notable withheld votes for Smith. They ratified KPMG LLP as auditors for the fiscal year through January 31, 2026, with overwhelming support. Advisory approval passed for executive compensation. Governance continuity holds firm.
10-Q
Q1 FY2026 results
Phreesia posted solid Q1 FY2026 results, with total revenue climbing 15% year-over-year to $115.9M, fueled by 16% growth in subscription services to $54.4M, 11% in payment processing to $29.9M, and 15% in network solutions to $31.7M; quarter-over-quarter, revenue rose from $110.1M (derived). Operating loss narrowed sharply to $3.3M from $19.4M a year ago, thanks to 19% cuts in sales and marketing and 14% in general and administrative expenses, while gross margin held steady around 86%. Diluted EPS improved to -$0.07 from -$0.35, aligning with 58.9M weighted shares and no anti-dilution flags. Cash swelled to $90.9M, up $6.7M sequentially, with operating cash flow at $14.9M and free cash flow at $7.5M after $7.4M in capex; total debt sits at $14.5M, mostly finance leases, backed by a $50M undrawn revolver. No major M&A this quarter. Yet competition from EHR giants looms large.
8-K
Phreesia Q1 revenue up 15%
Phreesia kicked off fiscal 2026 with Q1 revenue of $115.9 million, up 15% year-over-year, fueled by 9% growth in average healthcare services clients to 4,411 and 6% higher revenue per client. Net loss narrowed to $3.9 million from $19.7 million, while Adjusted EBITDA soared to $20.8 million, reflecting sharp operating leverage. Cash hit $90.9 million, with free cash flow turning positive at $7.5 million. The company held its full-year revenue guidance at $472–$482 million but lifted Adjusted EBITDA to $85–$90 million. Momentum builds, yet competitive pressures loom.
IPO
Website
Employees
Sector
Industry
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.39+0.00
DH
Definitive Healthcare Corp.
2.77-0.17
FORA
Forian Inc.
2.33-0.02
HSTM
HealthStream, Inc.
24.60-1.23
HYDTF
Hydreight Technologies Inc
3.28-0.09
PAXH
PreAxia Health Care Payment Sys
0.22+0.00
PRVA
Privia Health Group, Inc.
25.60-0.33
SOPH
SOPHiA GENETICS SA
4.54+0.45
TDOC
Teladoc Health, Inc.
8.23-0.13
WEAV
Weave Communications, Inc.
6.58-0.42